[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632259":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":134,"collaborators":25,"id":136,"slug":25,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":137,"sex":143,"minAge":144,"maxAge":25,"enrollmentInfo":145,"targetDuration":25,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Kardigan, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tonlamarsen","EXPERIMENTAL","3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)",[13],"Drug: Tonlamarsen",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Kardigan Clinical Study Information Team","CONTACT","+1-877-310-5135","clinicaltrials@kardigan.bio",[36,51,64,75,87,99,111,123],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Western Nephrology and Metabolic Bone Disease, PC - Arvada","RECRUITING","Arvada","Colorado","80002","United States",{"type":44,"coordinates":45},"Point",[46,47],-105.08748,39.80276,{"lat":47,"lon":46},[50],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"facility":52,"status":38,"city":53,"state":54,"zip":55,"country":42,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Homestead Associates in Research","Homestead","Florida","33033",{"type":44,"coordinates":57},[58,59],-80.47756,25.46872,{"lat":59,"lon":58},[62],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},"1-877-310-5135",{"facility":65,"status":38,"city":66,"state":54,"zip":67,"country":42,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Progressive Medical Research","Port Orange","32127",{"type":44,"coordinates":69},[70,71],-80.99561,29.13832,{"lat":71,"lon":70},[74],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"facility":76,"status":38,"city":77,"state":78,"zip":79,"country":42,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Richmond University Medical Center (RUMC)","Staten Island","New York","10310",{"type":44,"coordinates":81},[82,83],-74.13986,40.56233,{"lat":83,"lon":82},[86],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},{"facility":88,"status":38,"city":89,"state":90,"zip":91,"country":42,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Research Innovations, LLC","Beavercreek","Ohio","05431",{"type":44,"coordinates":93},[94,95],-84.06327,39.70923,{"lat":95,"lon":94},[98],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},{"facility":100,"status":38,"city":101,"state":102,"zip":103,"country":42,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Chattanooga Research & Medicine CHARM","Chattanooga","Tennessee","37404",{"type":44,"coordinates":105},[106,107],-85.30968,35.04563,{"lat":107,"lon":106},[110],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},{"facility":112,"status":38,"city":113,"state":114,"zip":115,"country":42,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Laguna Clinical Research Associates","Laredo","Texas","78041",{"type":44,"coordinates":117},[118,119],-99.50754,27.50641,{"lat":119,"lon":118},[122],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},{"facility":124,"status":38,"city":125,"state":114,"zip":126,"country":42,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Baylor Scott and White Research Institute - Temple","Temple","76502",{"type":44,"coordinates":128},[129,130],-97.34278,31.09823,{"lat":130,"lon":129},[133],{"name":31,"role":32,"phone":63,"phoneExt":25,"email":34},{"type":135,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100632259",false,"NCT07511361","Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part Study to Evaluate the Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension","KARDINAL-ASH","Key Inclusion Criteria:\n\n* Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg\u002Fm2\n* Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and\u002For treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and\u002For DBP ≥ 110 mmHg) occurred, as measured by a healthcare provider (HCP) within the 24 hours preceding hospitalization or during the initial 24 hours of hospitalization\n* At Screening and Randomization visit, average resting office systolic blood pressure ≥ 145 mmHg\n* Presence of established cardiovascular or renal disease\n\nKey Exclusion Criteria:\n\n* Has known history of secondary hypertension\n* Any malignancy requiring treatment within 5 years (except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated)\n* Has abnormal thyroid function with clinical significance\n* Recent hospitalization for stroke, myocardial infarction or coronary revascularization within 30 days prior to screening\n* History of and\u002For obvious clinical signs or symptoms of cirrhosis or other significant liver disease\n* Alanine aminotransferase or aspartate aminotransferase \\>2 x upper limit of normal\n* Most recent hospitalization was for non-cardiovascular or non-renal conditions","ALL","18 Years",{"count":146,"type":147},140,"ESTIMATED","INTERVENTIONAL",[150],"PHASE2","The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.",[153,154,155,156],"Hypertension","Acute Severe Hypertension","Hypertensive Emergency","Hypertensive Urgency","2026-06-29",{"date":159,"type":160},"2026-07-01","ACTUAL",{"date":162,"type":160},"2026-06-23",{"date":164,"type":147},"2027-02",{"name":5,"class":6},8]